Global Hyperimmune Globulins Industry Growth and Trends Forecast to 2031

Summary

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides passive immunity to the patient against an agent. This is in contrast to vaccines that provide active immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant passive short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides passive immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

According to APO Research, The global Hyperimmune Globulins market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Hyperimmune Globulins is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Hyperimmune Globulins is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Hyperimmune Globulins is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Hyperimmune Globulins include CSL Behring, Grifols, Biotest, Kedrion, CBPO, Emergent (Cangene), Kamada, CNBG and Hualan Bio, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hyperimmune Globulins, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperimmune Globulins.
The Hyperimmune Globulins market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperimmune Globulins market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Hyperimmune Globulins Segment by Company

CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Hyperimmune Globulins Segment by Type

Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Other
Hyperimmune Globulins Segment by Application

Government Institutions
Private Sector
Other
Hyperimmune Globulins Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Globulins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Globulins and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Globulins.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Hyperimmune Globulins Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Hyperimmune Globulins Sales Estimates and Forecasts (2020-2031)
1.3 Hyperimmune Globulins Market by Type
1.3.1 Hepatitis B Immunoglobulins
1.3.2 Rabies Immunoglobulins
1.3.3 Tetanus Immunoglobulins
1.3.4 Rho(D) Immunoglobulins
1.3.5 Other
1.4 Global Hyperimmune Globulins Market Size by Type
1.4.1 Global Hyperimmune Globulins Market Size Overview by Type (2020-2031)
1.4.2 Global Hyperimmune Globulins Historic Market Size Review by Type (2020-2025)
1.4.3 Global Hyperimmune Globulins Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Hyperimmune Globulins Sales Breakdown by Type (2020-2025)
1.5.2 Europe Hyperimmune Globulins Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Hyperimmune Globulins Sales Breakdown by Type (2020-2025)
1.5.4 South America Hyperimmune Globulins Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Hyperimmune Globulins Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Hyperimmune Globulins Industry Trends
2.2 Hyperimmune Globulins Industry Drivers
2.3 Hyperimmune Globulins Industry Opportunities and Challenges
2.4 Hyperimmune Globulins Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Hyperimmune Globulins Revenue (2020-2025)
3.2 Global Top Players by Hyperimmune Globulins Sales (2020-2025)
3.3 Global Top Players by Hyperimmune Globulins Price (2020-2025)
3.4 Global Hyperimmune Globulins Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Hyperimmune Globulins Major Company Production Sites & Headquarters
3.6 Global Hyperimmune Globulins Company, Product Type & Application
3.7 Global Hyperimmune Globulins Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Hyperimmune Globulins Market CR5 and HHI
3.8.2 Global Top 5 and 10 Hyperimmune Globulins Players Market Share by Revenue in 2024
3.8.3 2023 Hyperimmune Globulins Tier 1, Tier 2, and Tier 3
4 Hyperimmune Globulins Regional Status and Outlook
4.1 Global Hyperimmune Globulins Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Hyperimmune Globulins Historic Market Size by Region
4.2.1 Global Hyperimmune Globulins Sales in Volume by Region (2020-2025)
4.2.2 Global Hyperimmune Globulins Sales in Value by Region (2020-2025)
4.2.3 Global Hyperimmune Globulins Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Hyperimmune Globulins Forecasted Market Size by Region
4.3.1 Global Hyperimmune Globulins Sales in Volume by Region (2026-2031)
4.3.2 Global Hyperimmune Globulins Sales in Value by Region (2026-2031)
4.3.3 Global Hyperimmune Globulins Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Hyperimmune Globulins by Application
5.1 Hyperimmune Globulins Market by Application
5.1.1 Government Institutions
5.1.2 Private Sector
5.1.3 Other
5.2 Global Hyperimmune Globulins Market Size by Application
5.2.1 Global Hyperimmune Globulins Market Size Overview by Application (2020-2031)
5.2.2 Global Hyperimmune Globulins Historic Market Size Review by Application (2020-2025)
5.2.3 Global Hyperimmune Globulins Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Hyperimmune Globulins Sales Breakdown by Application (2020-2025)
5.3.2 Europe Hyperimmune Globulins Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Hyperimmune Globulins Sales Breakdown by Application (2020-2025)
5.3.4 South America Hyperimmune Globulins Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Hyperimmune Globulins Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 CSL Behring
6.1.1 CSL Behring Comapny Information
6.1.2 CSL Behring Business Overview
6.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
6.1.5 CSL Behring Recent Developments
6.2 Grifols
6.2.1 Grifols Comapny Information
6.2.2 Grifols Business Overview
6.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Grifols Hyperimmune Globulins Product Portfolio
6.2.5 Grifols Recent Developments
6.3 Biotest
6.3.1 Biotest Comapny Information
6.3.2 Biotest Business Overview
6.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Biotest Hyperimmune Globulins Product Portfolio
6.3.5 Biotest Recent Developments
6.4 Kedrion
6.4.1 Kedrion Comapny Information
6.4.2 Kedrion Business Overview
6.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Kedrion Hyperimmune Globulins Product Portfolio
6.4.5 Kedrion Recent Developments
6.5 CBPO
6.5.1 CBPO Comapny Information
6.5.2 CBPO Business Overview
6.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.5.4 CBPO Hyperimmune Globulins Product Portfolio
6.5.5 CBPO Recent Developments
6.6 Emergent (Cangene)
6.6.1 Emergent (Cangene) Comapny Information
6.6.2 Emergent (Cangene) Business Overview
6.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
6.6.5 Emergent (Cangene) Recent Developments
6.7 Kamada
6.7.1 Kamada Comapny Information
6.7.2 Kamada Business Overview
6.7.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Kamada Hyperimmune Globulins Product Portfolio
6.7.5 Kamada Recent Developments
6.8 CNBG
6.8.1 CNBG Comapny Information
6.8.2 CNBG Business Overview
6.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.8.4 CNBG Hyperimmune Globulins Product Portfolio
6.8.5 CNBG Recent Developments
6.9 Hualan Bio
6.9.1 Hualan Bio Comapny Information
6.9.2 Hualan Bio Business Overview
6.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
6.9.5 Hualan Bio Recent Developments
6.10 Shanghai RAAS
6.10.1 Shanghai RAAS Comapny Information
6.10.2 Shanghai RAAS Business Overview
6.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
6.10.5 Shanghai RAAS Recent Developments
6.11 Sichuan Yuanda Shuyang
6.11.1 Sichuan Yuanda Shuyang Comapny Information
6.11.2 Sichuan Yuanda Shuyang Business Overview
6.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
6.11.5 Sichuan Yuanda Shuyang Recent Developments
6.12 ADMA Biologics
6.12.1 ADMA Biologics Comapny Information
6.12.2 ADMA Biologics Business Overview
6.12.3 ADMA Biologics Hyperimmune Globulins Sales, Revenue and Gross Margin (2020-2025)
6.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
6.12.5 ADMA Biologics Recent Developments
7 North America by Country
7.1 North America Hyperimmune Globulins Sales by Country
7.1.1 North America Hyperimmune Globulins Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Hyperimmune Globulins Sales by Country (2020-2025)
7.1.3 North America Hyperimmune Globulins Sales Forecast by Country (2026-2031)
7.2 North America Hyperimmune Globulins Market Size by Country
7.2.1 North America Hyperimmune Globulins Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Hyperimmune Globulins Market Size by Country (2020-2025)
7.2.3 North America Hyperimmune Globulins Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Hyperimmune Globulins Sales by Country
8.1.1 Europe Hyperimmune Globulins Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Hyperimmune Globulins Sales by Country (2020-2025)
8.1.3 Europe Hyperimmune Globulins Sales Forecast by Country (2026-2031)
8.2 Europe Hyperimmune Globulins Market Size by Country
8.2.1 Europe Hyperimmune Globulins Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Hyperimmune Globulins Market Size by Country (2020-2025)
8.2.3 Europe Hyperimmune Globulins Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Hyperimmune Globulins Sales by Country
9.1.1 Asia-Pacific Hyperimmune Globulins Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Hyperimmune Globulins Sales by Country (2020-2025)
9.1.3 Asia-Pacific Hyperimmune Globulins Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Hyperimmune Globulins Market Size by Country
9.2.1 Asia-Pacific Hyperimmune Globulins Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Hyperimmune Globulins Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Hyperimmune Globulins Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Hyperimmune Globulins Sales by Country
10.1.1 South America Hyperimmune Globulins Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Hyperimmune Globulins Sales by Country (2020-2025)
10.1.3 South America Hyperimmune Globulins Sales Forecast by Country (2026-2031)
10.2 South America Hyperimmune Globulins Market Size by Country
10.2.1 South America Hyperimmune Globulins Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Hyperimmune Globulins Market Size by Country (2020-2025)
10.2.3 South America Hyperimmune Globulins Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Hyperimmune Globulins Sales by Country
11.1.1 Middle East and Africa Hyperimmune Globulins Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Hyperimmune Globulins Sales by Country (2020-2025)
11.1.3 Middle East and Africa Hyperimmune Globulins Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Hyperimmune Globulins Market Size by Country
11.2.1 Middle East and Africa Hyperimmune Globulins Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Hyperimmune Globulins Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Hyperimmune Globulins Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Hyperimmune Globulins Value Chain Analysis
12.1.1 Hyperimmune Globulins Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Hyperimmune Globulins Production Mode & Process
12.2 Hyperimmune Globulins Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Hyperimmune Globulins Distributors
12.2.3 Hyperimmune Globulins Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings